RE:RE:RE:RE:RE:RE:Pfizer "The most appealing partners for ADCs are those that offer additive or synergistic effects on tumor cells or their microenvironment without unacceptable overlapping toxicities."
However the 2020 Roche sponsored KATE2 study, the only published randomized trial testing an ADC plus an ICI, compared trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in patients with pretreated HER2+ breast cancer, failed to improve progression-free survival (PFS) (median 8.2 vs 6.2 months, respectively, P = 0.33).
And this ADC + ICI combination failure serves as a reason for why ONCY's pelareorep is the most favorable addition to either Pfizer's or Roche's ADC product pipeline and platform, when used in combination with immune checkpoint inhibitors, as a triplet I/O combination therapy.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30465-4/abstract